What is Lantheus Holdings's market cap?

Lantheus Holdings (LNTH) has a market capitalization of $6.6B and trades on NASDAQ.

What is Lantheus Holdings's revenue and profitability?

Lantheus Holdings generated $1.6B in trailing twelve-month revenue with net income of $275.3M, representing a net margin of 17.7%. Gross margin stands at 60.1%, with free cash flow of $387.8M. The latest reported period is Q2 2026.

Who are Lantheus Holdings's competitors?

Lantheus Holdings's key competitors include GE HealthCare, VolitionRX Limited Common Stock, Perspective Therapeutics, Inc., and others. These companies compete in similar markets and product categories.

Who does Lantheus Holdings partner with?

Lantheus Holdings's notable partners include SHINE Technologies, LLC, AstraZeneca AB, Radiopharm Theranostics Limited.

What subsidiaries does Lantheus Holdings have?

Lantheus Holdings's subsidiaries include Evergreen Theragnostics, Inc., Lantheus Biosciences Ltd..

Where is Lantheus Holdings headquartered?

Lantheus Holdings is headquartered in United States of America and employs approximately 834 people. It has been publicly traded since 2015.

Lantheus Holdings (LNTH) Stock Fundamentals & Financials

Lantheus Holdings is a leading radiopharmaceutical-focused company dedicated to enabling clinicians to detect, treat, and monitor diseases through its 'Find, Fight and Follow' strategy.

Market cap

$6.57B+89.9%

Revenue$1.6B+2.4%

Net income$275.3M-2.7%

Free cash flow$387.8M-19.0%

EPS (diluted)$4.13+5.1%

Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 6, 2026

Revenue$388.2MBeat by $25.0M EPS$1.55Beat by $0.25

Read the full report

Next report

Nov 5, 2026 (in 2 months)

Revenue estimate$360.9M

EPS estimate$1.25

Financials

Q2 2026

Income statement

See full

Revenue$388.2M+2.7%

Gross profit$241.9M+0.4%

Operating income$100.2M+13.9%

Net income$75.0M-4.7%

EPS (diluted)$1.11-0.9%

Balance sheet

See full

Cash & equivalents$595.0M-14.7%

Total debt$626.8M+1.5%

Total equity$1.3B+12.4%

Total assets$2.4B+14.1%

Cash flow

See full

Operating cash flow$92.2M+5.9%

CapEx$2.3M-70.7%

Free cash flow$89.9M+13.5%

Valuation & ratios

Valuation

See full

Market cap$6.57B+89.9%

Enterprise value$6.6B+95.3%

P/E23.9×+11.6×

P/S4.2×+1.9×

Profitability

See full

Gross margin60.1%-3.6pp

Operating margin19.4%-9.4pp

Net margin17.7%-0.9pp

FCF margin24.9%-6.6pp

Returns & leverage

See full

Return on equity22.2%-3.6pp

Debt / equity0.5×-0.1×

Current ratio3.1×-1.2×

Segments

By product

See full

Oncology$240.4M—

PYLARIFY$240.4M-4.1%

Cardiology$88.3M—

Definity$88.3M+5.2%

Neuraceq$39.6M—

Competitors

By market cap

GE HealthCare Technologies$28.7B-18.0%

Lantheus Holdings$6.6B+89.9%

Perspective Therapeutics$308.2M+36.5%

Actinium Pharmaceuticals$39.0M-22.4%

Lantern Pharma$24.7M-41.6%

Cellectar Biosciences$22.2M+37.5%

Citius Pharmaceuticals$15.4M-23.4%

VolitionRX Limited$7.7M-88.6%

By revenue growth

GE HealthCare Technologies+6.5%

Lantheus Holdings+2.4%

By net margin

Lantheus Holdings17.69%-0.9pp

GE HealthCare Technologies9.33%-1.9pp

Perspective Therapeutics-218.35%—

Profile

Lantheus Holdings is a leading radiopharmaceutical-focused company dedicated to enabling clinicians to detect, treat, and monitor diseases through its 'Find, Fight and Follow' strategy. The company provides innovative positron emission tomography (PET) radiodiagnostics, microbubbles, and therapeutic agents primarily for oncology and neurology. Its core value proposition lies in delivering precision diagnostic information that improves patient outcomes, reduces clinical risk, and optimizes healthcare costs.

Competitive position

A market leader in radiopharmaceuticals transitioning its focus from legacy SPECT products toward high-growth PET diagnostics and therapeutic assets.

GeographiesUnited States, Canada, Europe, Asia-Pacific, South America

Customer segmentsHospitals, Imaging Centers, Government Facilities, Pharmaceutical Companies

Business modelProduct manufacturing and sales, Contract Development and Manufacturing (CDMO), Licensing and Royalties

SuppliersRadioisotope suppliers, Specialized chemical manufacturers, Clinical research organizations

CustomersHospitals, Independent imaging centers, Government healthcare facilities, Pharmaceutical partners

CountryUnited States of America

Listed2015

Employees834.0

CEOMary Anne Heino

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websitelantheus.com

FilingsSEC EDGAR

FAQ

What is Lantheus Holdings's market cap?: Lantheus Holdings (LNTH) has a market capitalization of $6.6B and trades on NASDAQ.
What is Lantheus Holdings's revenue and profitability?: Lantheus Holdings generated $1.6B in trailing twelve-month revenue with net income of $275.3M, representing a net margin of 17.7%. Gross margin stands at 60.1%, with free cash flow of $387.8M. The latest reported period is Q2 2026.
Who are Lantheus Holdings's competitors?: Lantheus Holdings's key competitors include GE HealthCare, VolitionRX Limited Common Stock, Perspective Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
Who does Lantheus Holdings partner with?: Lantheus Holdings's notable partners include SHINE Technologies, LLC, AstraZeneca AB, Radiopharm Theranostics Limited.
What subsidiaries does Lantheus Holdings have?: Lantheus Holdings's subsidiaries include Evergreen Theragnostics, Inc., Lantheus Biosciences Ltd..
Where is Lantheus Holdings headquartered?: Lantheus Holdings is headquartered in United States of America and employs approximately 834 people. It has been publicly traded since 2015.

Ask your AI about Lantheus Holdings.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude